SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001493152-23-024051 from ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics, Inc.
Date: July 7, 2023 · CIK: 0001859007 · Accession: 0001493152-23-024051

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
July 7, 2023
Author
Director
Form
CORRESP
Company
ZyVersa Therapeutics, Inc.

Letter

A.G.P./ALLIANCE GLOBAL PARTNERS

Madison Avenue 28th Floor New York,

New York 10022

July 7, 2023

VIA EDGAR

Securities and Exchange Commission

100 F Street, N.E.

Division of Corporation Finance

Washington, D.C. 20549

Re: ZyVersa Therapeutics, Inc. (the “Company”)

Registration Statement on Form S-1

File No. 333- 272657 (the “Registration Statement”)

Ladies and Gentlemen:

In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, (the “Act”), A.G.P./Alliance Global Partners, as the sole placement agent, hereby joins the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 5:00 p.m., Eastern Time on July 10, 2023, or as soon thereafter as practicable.

The undersigned, as the sole placement agent, represents that it has and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Please contact Katherine J. Blair of Manatt, Phelps & Phillips, LLP, counsel of the placement agent, at (310) 312-4252 to provide notice of effectiveness, or if you have any questions or concerns regarding the foregoing. We appreciate your assistance in this matter.

[Signature page follows]

Very
truly yours,
A.G.P./ALLIANCE
GLOBAL PARTNERS

Show Raw Text
CORRESP
1
filename1.htm

A.G.P./ALLIANCE
GLOBAL PARTNERS

590
Madison Avenue 28th Floor New York,

New
York 10022

July
7, 2023

VIA
EDGAR

Securities
and Exchange Commission

100 F Street, N.E.

Division
of Corporation Finance

Washington,
D.C. 20549

  Re:
  ZyVersa Therapeutics, Inc. (the “Company”)

  Registration Statement on Form S-1

  File No. 333- 272657 (the “Registration Statement”)

Ladies
and Gentlemen:

In
accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, (the “Act”),
A.G.P./Alliance Global Partners, as the sole placement agent, hereby joins the Company’s request for acceleration of the above-referenced
Registration Statement, requesting effectiveness for 5:00 p.m., Eastern Time on July 10, 2023, or as soon thereafter as practicable.

The
undersigned, as the sole placement agent, represents that it has and will comply with the requirements of Rule 15c2-8 under the Securities
Exchange Act of 1934, as amended.

Please
contact Katherine J. Blair of Manatt, Phelps & Phillips, LLP, counsel of the placement agent, at (310) 312-4252 to provide notice
of effectiveness, or if you have any questions or concerns regarding the foregoing. We appreciate your assistance in this matter.

[Signature
page follows]

    Very
    truly yours,

    A.G.P./ALLIANCE
    GLOBAL PARTNERS

    By:

    /s/
    Thomas Higgins

    Name:

    Thomas
    Higgins

    Title:

    Managing
    Director